JRF Ortho to Reach More Patients in Need of Fresh, “Living” Cartilage

OneLegacy, the nation’s largest organ, eye and tissue procurement organization, has expanded its reach of helping more people lead healthier lives through its new commitment to provide fresh, “living” cartilage to the nonprofit JRF Ortho. This cartilage, which can be used by surgeons throughout the world, will allow more people to walk and will allow young athletes to more easily continue to pursue their passion.

“There is an incredible need for fresh tissue from young donors that can be placed in the knee, ankle or other joints of waiting patients to dramatically improve movement and quality of life,” said Diane Wilson, chairman of the board of JRF Ortho. “Thankfully OneLegacy has stepped up to meet this challenge, and because of them we can expect to see superior clinical results and even more positive patient outcomes from those we serve.”

Fresh tissue—that which is not frozen or embedded in preservatives—can be used to replace and repair defects in articulating joints or torn or damaged meniscus. In many cases fresh grafts allow mobility that couldn’t be accomplished with alternate grafts or prostheses. The challenge is that these live, living cells need to be transplanted within 28 days of processing; and few organizations have been able to make the commitment to achieve that high standard. Now OneLegacy has.

Click here to read the entire press release..

Share this:

Wider adoption of contrast-enhanced ultrasound (CEUS)

Dr. Brian Cole and Steve Kashul talk with Dr. Steven Feinstein about the use of Contrast Enhanced Ultrasound Imaging and the prevention of heart attacks and strokes. Dr. Feinstein developed the first two FDA approved ultrasound contrast agents and is recognized as one of the leading pioneers in the development of non-invasive contrast-enhanced ultrasound (CEUS) imaging techniques. Dr. Feinstein is a Professor at the Department of Internal Medicine, Rush Medical College.

Contrast-enhanced ultrasound (CEUS) offers a new, safe, radiation-free modality to help problem-solve diagnostic questions in a wide range of clinical applications, according to an article published by researchers from the Department of Radiology and Biomedical Imaging at University of California San Francisco.Steven B. Feinstein, MD practices Cardiovascular Disease in Chicago

Ultrasound contrast agents have been in use throughout most of the world and have been used off-label in the United State for over a decade. In addition to the use of ultrasound contrast agents in cardiac imaging, the FDA recently approved their use in liver imaging for both paediatric and adult patients, and for use in the urinary tract (voiding ultrasonography) in paediatric patients for evaluation of suspected or known vesicoureteral reflux (VUR).

The recent FDA approvals are likely to spur wider adoption of CEUS, says the article, which details the modality’s key advantages. Since the contrast agents are excreted by the lungs they are safe in patients with renal and/or liver dysfunction whom otherwise may not be able to undergo a contrast-enhanced evaluation. Also, CEUS provides unique advantages and can improve visualisation of blood flow and tissue vascularity.

Carson Lux, PT, SFG-I, 3DMAPS, FMS/SFMAAlso in this segment is a conversation with Carson Lux, a physical therapist and Program Head in the Movement Performance Project at Athletico Physical Therapy. Carson shares his 30 years of experience after graduating from the University of Evansville in 1989. He played HS football, basketball, collegiate baseball, and studied Aikido. Carson subsequently has undergone multiple orthopedic surgeries as a result of his own athletic career and has a unique understanding of what athletes must endure to return to their sports and the current therapy techniques to speed injury rehabilitation.

Share this:

LSU ACL study aims to advance sports medicine into new era: ‘This is a big deal’


Tight end Jamal Pettigrew stepped through footwork drills, blocked dummies, pivoted and cut through routes in the LSU indoor practice facility — standard stuff, except for one thing: Pettigrew had only surgically repaired his torn anterior cruciate ligament (ACL) four months before, which, according to experts, meant he’d returned to football activities nearly twice as fast as the average athlete.

A few days later, outside linebacker K’Lavon Chaisson wore sweats as he tossed around a football during pregame warmups at Kyle Field in College Station, Texas. He’d suffered a torn ACL against Miami on Sept. 2, tweeted a picture post-surgery Sept. 20, and less than two months later, tweeted a video of himself sprinting across LSU’s outdoor practice facility.

Plenty of torn ACLs with high-profile NFL athletes have played out publicly. Tom Brady. Jamaal Charles. Adrian Peterson famously returned to the Minnesota Vikings from a 2012 ACL tear in nine months — and that was widely considered unthinkable.

What was going on at LSU?

Dr. Brian Cole and Steve Kashul discuss their thoughts and opinions on this article comparing alternate ACL repair methods.

Sports Medicine Weekly on 670 The Score

Share this:

Clinical Trial to Repair Articular Cartilage Defects of the Knee

Dr. Brian Cole talks with Chris Zlevor, a patient who experienced three knee surguries before participating in the Aesculap Novacart 3D Clinical Trial. This discussion covers the process of participation and followup experience as a patient in the study. Aesculap Biologics focuses on the manufacturing of tissue engineered products for the regeneration of diseased or damaged joint tissues.

A Phase 3 clinical trial is currently being conducted for NOVOCART 3D, a tissue engineered cell-based product designed to repair articular cartilage defects of the knee. If you believe you or your patients might qualify for one of our clinical trials or wish to be evaluated, please contact our research administrator, Kavita Ahuja, MD at (312) 563-2214 or kavita.ahuja@rushortho.com or inquire at your next visit.

Share this: